Let food be thy medicine: the role of diet in colorectal cancer: a narrative review

Introduction

According to the latest global burden of cancer data for 2020 released by the International Agency for Research on Cancer (IARC) within the World Health Organization (WHO), more than 1.93 million people worldwide were newly diagnosed with colorectal cancer (CRC), accounting for 10% of all newly diagnosed cancers worldwide and ranking third in incidence and second in mortality at 9.4% (1). In 2020, a total of 555,477 new cases of CRC and 286,162 CRC-related deaths occurred in China, and CRC ranked second (12.2%) and fifth (9.5%) for these statistics, respectively, among all cancers (1). The 5-year relative survival rate of CRC in China from 2012 to 2015 was only 52.7% (2). Current cancer treatments, such as surgery, chemoradiotherapy, immune checkpoint inhibitors, and molecular targeted drugs, have evolved and improved the prognosis of cancer patients, but limitations remain (3).

A variety of healthy dietary patterns have evolved with the development of human civilization, including the Mediterranean diet (MD), the Dietary Approaches to Stop Hypertension (DASH) diet, and fasting. For example, the MD emphasizes the consumption of plenty of fruits and vegetables, whole grains, and a small amount of red meat, with olive oil as the main dietary fat (4). Recent studies found that various dietary patterns are closely related to the occurrence, development, and prognosis of cancer. The present review focuses on different dietary patterns and factors. We present the following article in accordance with the Narrative Review reporting checklist (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-32/rc).

Methods

Table 1 shows the search strategy summary. In this review, we searched the PubMed and Embase databases for original articles reporting the results of preclinical and clinical trials published from 2000 to 2021 with the keywords “diet”, “colorectal cancer”, “dietary pattern” and “dietary factor”. The articles were limited to full-text publications in English. Studies on the use of the dietary pattern or factor in patients at high risk of CRC and in those with CRC were included.

Effects of different dietary patterns on CRC

Table 2 summarizes the role of different dietary patterns in the prevention and treatment of CRC.

MD

The MD was originally consumed by people along the Mediterranean coast. Observational studies in the 1950s found that these people had lower rates of cancer than people in other parts of Europe. Since the MD was recognized and regarded as a healthy dietary pattern (30). The current MD is characterized by a high intake of vegetables, legumes, fresh fruits, whole grains and nuts, with olive oil (generally virgin olive oil with less than 0.8% acidity obtained via mechanical extraction) as the main dietary fat, and moderate consumption of fish, dairy products (primarily cheese and skim milk), red meat and red wine (5). With the development of modern medicine, an increasing number of studies have found that food emphasized in this diet protects against many diseases, such as cardiovascular disease, breast cancer, and asthma (31).

Researchers recently reported that the MD decreases the risk of CRC. For example, Zhong et al. (6) in 2020 performed a meta-analysis of 13 prospective cohort studies and found a 10% reduction in CRC incidence associated with MD compliance. The meta-analysis by Schwingshackl et al. (7) included 21 cohort studies and 12 case-control studies, comprising 1,368,736 and 62,725 subjects, respectively, and the results showed that high compliance with the MD reduced the risk of CRC by 15%. Rosato et al. (8) retrospectively analyzed 3,745 cases of CRC and 6,804 cases of non-CRC in Italy and found that the MD reduced the incidence of CRC.

More recent reports have consistently shown that adherence to the MD before or after CRC diagnosis reduced CRC mortality. For example, Van Blarigan et al. (9) observed the diet of 1,284 patients with metastatic CRC within 4 weeks after treatment, and introduced the concept of an alternative Mediterranean diet (AMED) score based on the work of Fung et al. (32). The results showed that a higher AMED score negatively correlated with the mortality of patients with CRC. Jacobs et al. (10) also reported that adherence to a diet with a high AMED score before diagnosis reduced CRC mortality. Bloomfield et al. (11) performed a cohort study and showed that consumption of the MD without limiting fat intake reduced mortality among CRC patients.

DASH diet

The DASH diet is a treatment for high blood pressure that originated with the large hypertension prevention and treatment program created by the National Heart, Lung, and Blood Institute (NHLBI) in 1997. It emphasizes higher intakes of fruits, vegetables, legumes, and nuts; moderate intake of low-fat dairy products; lower intake of animal protein; and a controlled salt intake (12). The DASH diet has beneficial effects on high blood pressure, diabetes, and breast cancer (33).

Notably, the DASH diet was recently associated with a lower incidence of CRC. For example, a meta-analysis by Tangestani et al. (14) also found a significant negative association between adherence to the DASH diet and CRC risk. Vargas et al. (15) evaluated 938 women in a cross-sectional study and found that the patients who strictly followed the DASH diet recommendations had a lower risk of CRC.

Although the DASH diet was associated with a reduced risk of CRC, it was unclear whether this dietary pattern has a positive effect on CRC treatment. Jacobs et al. (10) reported no significant association between the DASH diet and CRC mortality; this result is consistent with Fung et al. (13). A prospective cohort study of patients with metastatic CRC also concluded that the DASH diet did not extend survival (9).

Fasting

Fasting, which originated from European religions, is considered a green, or nature, therapy that entails the consumption of a moderate amount of drinking water and a small amount of vegetable juice and fruit juice while fasting from all other food for a limited period of time; adherents to this diet rely on energy stored in the body to support life activities (16). This particular approach alters energy metabolism and affects the course of a variety of diseases, such as inflammatory bowel disease (IBD) (34) and breast cancer (35).

Fasting-based diets in the field of oncology include simple fasting and the fasting-mimicking diet (FMD) (36). The FMD is a plant-based, low-calorie, low-protein, and low-carbohydrate diet designed to mimic fasting while providing adequate micronutrients (vitamins, minerals, etc.) and minimizing the burden of fasting. Originally proposed by Brandhorst et al. (17), the FMD is a cyclical diet (600 kcal on day 1; 300 kcal on days 2 to 5) interspersed with periods of a normal feeding regimen. With the further development of FMD research, many diets with similar characteristics and cycles have emerged (17,35).

Fasting is the most effective nutritional intervention for the prevention and treatment of CRC because it changes the energy metabolism in CRC cells, inhibits CRC cell growth, prolongs patients’ survival, and delays disease progression (37). Preclinical studies have confirmed these effects. For example, Yamamoto et al. (38) showed a significant reduction in the incidence and number of colorectal tumors in the calorie-restricted diet group compared to the free diet group. Weng et al. (39) studied the effects of fasting on glucose metabolism and CRC malignant behavior and found that fasting inhibited CRC cells in proliferation in combination with mammalian target of rapamycin (mTOR) inhibitors.

However, it is difficult for most people, especially cancer patients, to adhere to fasting for a long time. Therefore, the FMD is primarily used instead of fasting in clinical studies, and related studies remain in the exploratory stage. For example, Brandhorst et al. (17) performed an initial randomized controlled clinical trial with 38 subjects and found that the FMD group had a lower risk of CRC than the control group.

Vegetarian diet

Vegetarian diets originated in 3200 BC when ancient Egyptian civilizations started adopting vegetarianism (40). Approximately 100 years ago, researchers began identifying potential health benefits of vegetarian diets. According to the Vegetarian Society (18), a vegetarian diet is characterized by the consumption of fruits, vegetables, legumes, pulses, grains, nuts, seeds, fungi, algae, yeast and/or other nonanimal-based foods, with or without dairy products, honey and/or eggs.

Previous prospective cohort studies and randomized clinical trials showed that a vegetarian diet reduced the risk of CRC. For example, Orlich et al. (19) studied 77,659 participants and found that those adhering to a vegetarian diet had a 22% lower risk of CRC than nonvegetarians. The cohort study by Gilsing et al. (20) followed 10,210 subjects for 20.3 years and observed a significant reduction in CRC risk in vegetarians compared to meat consumers. A cohort study of 10,998 subjects recorded 95 cases of CRC after an average follow-up of 17 years; in this study, vegetarians had a 15% lower risk of CRC compared to nonvegetarians (21).

Although some studies have reported positive results for a vegetarian diet in preventing and treating CRC, others have reported conflicting results. For example, Godos et al. (41) performed a meta-analysis of a vegetarian diet and the risk of CRC and found no significant association between a vegetarian diet and a lower risk of CRC. Erben et al. (42) also showed that a vegetarian diet did not significantly reduce the risk of CRC. Dinu et al. (43) reported that a vegetarian diet did not reduce the risk of death from CRC. A meta-analysis of several prospective studies by Ginter et al. (44) showed no significant difference in CRC-related mortality between vegetarians and “health-conscious” nonvegetarians.

Many factors may influence the effectiveness of a vegetarian diet in the prevention and treatment of CRC, such as whether the diet contains eggs and dairy products, the ethnicity of the vegetarians, and the location of their residence. More studies are needed to assess whether a specific vegetarian diet reduces the risk of CRC in a particular population in a particular region and whether a vegetarian diet has potential as an adjunct to CRC treatment.

Ketogenic diet (KD)

Researchers in the 1920s developed a high-fat, medium-protein, and low-carbohydrate diet called the KD to treat intractable epilepsy (22). The KD has been used to treat epilepsy and Alzheimer’s disease (45).

More preclinical studies have shown that the KD effectively slows CRC growth. For example, Zhang et al. (23) performed in vitro and in vivo studies with BALB/C mice and found that the KD prevented CRC progression by inducing oxidative stress, inhibiting matrix metallopeptidase-9 (MMP-9) expression, and enhancing the M2 to M1 polarization of tumor-associated macrophages (TAMs). Nakamura et al. (24) found that the KD suppressed CRC progression and significantly suppressed the systemic inflammatory response and muscle loss associated with cancer progression in an animal study.

Recent clinical trials also demonstrated that the KD has benefits in CRC treatment. For example, Klement et al. (25) studied a cohort 49 CRC patients undergoing radiotherapy, of which 24 adhered to a KD. The results showed that the KD significantly reduced body weight and fat mass, maintained skeletal muscle mass, and synergized with radiotherapy to evoke a trend of a pathological tumor response. Tulipan et al. (26) performed an online survey of 94 CRC patients and found that adherence to the KD during treatment was associated with improved self-reported quality of life. The strict KD improved CRC outcomes by promoting the switch to fat-free mass, one of the two human body components (fat and everything else) (27). Obesity is a well-established risk factor for CRC, and a strict KD reduced body fat percent and improved CRC patient survival (28). Klement et al. (29) initiated a phase I clinical trial to investigate whether an intermittent KD (such as eating a ketogenic breakfasts) after radiotherapy has a similar effect as a strict KD on the body composition of cancer patients. The results showed that the intermittent KD combined with concurrent radiotherapy had a significant beneficial effect on fat-free mass and protected normal tissue from ionizing radiation compared to the strict KD. These results demonstrate that the KD may have value in combination therapies to improve the efficacy of classical cancer therapy. However, more carefully designed and in-depth studies are needed.

Effects of different dietary factors on CRC

Based on the acknowledgment that dietary patterns rich in processed meat, red meat, and highly refined grains increase CRC risk and because of the prevalence of nutritional and micronutrient deficiencies in CRC patients, researchers investigated the influence of dietary elements on the development of CRC. The following paragraphs discusses the effects of factors, such as fats, dietary fiber (DF), and trace elements, on the incidence and progression of CRC.

DF

DF is a polysaccharide that is not digested in the gastrointestinal tract and produces no energy. The results of in-depth studies of intestinal bacteria have led to increased attention on DF, and DF supplements have been found to help prevent and treat depression, chronic obstructive pulmonary disease, and diabetes (46).

Researchers have shifted their attention to the relationship between the amount of DF consumed per day and the prevention of CRC in people at high risk of CRC. For example, Peto et al. (47) showed that diets high in fiber (≥23 g/day) reduced CRC risk by 12%. The Scientific Advisory Committee on Nutrition in the UK performed a meta-analysis of the role of DF and found that the risk of CRC decreased by 8% for each 7 g/day increase in DF intake from food (48). O'Keefe et al. (49) recommended that DF intake be increased to more than 50 g/day to prevent CRC.

Song et al. (50) performed a prospective cohort study of 1,575 CRC patients and found that those who increased their fiber intake from prediagnosis levels had lower mortality, and each additional 5 g/day of fiber intake was associated with an 18% reduction in CRC-specific mortality. Unfortunately, the global per capita intake of DF is less than 20 g/day (51).

Therefore, increasing DF consumption should be encouraged. Future studies should determine the precise recommended number of grams of DF intake for people at high risk of CRC. The effects of DF from different sources should also be compared to ascertain the source that will achieve the best therapeutic effect.

Dietary fats

The development of the modern society has led to the increasing common excessive intake of dietary fat, which may lead to obesity and chronic disease.

Animal and in vitro studies have shown a direct role for dietary fat in increasing colonic cell proliferation and associated risks (52-54). However, the results of clinical studies are complex and inconsistent. Wan et al. (55) performed a randomized controlled feeding trial of 217 people aged 18–35 years that lasted 6 months to compare a low-fat diet (20% fat energy), medium-fat diet (30% fat energy) and high-fat diet (40% fat energy). Intestinal floras populations associated with CRC increased in the high-fat diet group. Total fat, saturated fat, monounsaturated fat and n-6 polyunsaturated fat intake was not associated with CRC risk, according to the results of a case-control study (56). A meta-analysis by Kim et al. (57) showed no effect of dietary fat or fatty acids on CRC risk. Nakamura et al. (58) performed a randomized controlled trial of 373 patients after CRC surgery who were asked to consume at least 18–22% of total energy from fat. The results showed that tumor recurrence increased as fat intake decreased.

In contrast, omega-3 polyunsaturated fatty acids (PUFAs), such as α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may be protective agents against CRC (59). For example, Haidari et al. (60) showed that the combination of vitamin D (50,000 IU weekly) and omega-3 fatty acids (660 mg/day) reduced the levels of inflammation biomarkers in patients with CRC, improved the efficacy of chemotherapy drugs, and reduced the side effects of chemotherapy. Golkhalkhali et al. (61) demonstrated that supplementation with microbial cell preparations (MCPs) and omega-3 fatty acids (2 g/day for 8 weeks) improved the quality of life of patients with CRC and mitigated some side effects of chemotherapy. A randomized controlled trial evaluated 148 patients who were referred for elective CRC surgery and received an omega-3 fatty acids-enriched oral nutritional supplement (ONS: 2.0 g/day EPA and 1.0 g/day DHA) or a standard ONS for 7 days before surgery. The results showed that oral intake of omega-3 fatty acids had anti-inflammatory effects in surgical patients (62). Kim et al. (63) performed a meta-analysis of 20 prospective studies involving 18,102 cases and 1,360,046 participants and found that EPA and DHA intake was inversely associated with 11% and 12% lower CRC risk, respectively. The risk of CRC decreased 4% for every 1% increase in blood n-3 PUFA levels.

However, the effect of dietary fat on the prevention and treatment of CRC remains controversial, and more related clinical studies are needed to develop a better dietary fat intake plan.

Red and processed meats

Many epidemiological studies have examined the effects of red meat (e.g., beef, pork, and lamb) and processed meats. Most of these studies reported an association between an increased CRC risk and greater intake of red and processed meats. For example, a prospective study by the Health Professionals Follow-up Study (HPFS) reported that men who ate beef, pork or lamb more than five times per week had a threefold increased risk of CRC compared to men who ate less than one meal per month that included these meats (64). Bradbury et al. (65) followed 475,581 participants aged 40–69 years for an average of 5.7 years and identified 2,609 cases of CRC. In this study, participants who consumed an average of 76 g of red and processed meats daily had a 20% higher risk of CRC compared to those who consumed 21 g daily. Another prospective study (66) found that a higher daily intake of processed meat and barbequed/red meat products was associated with an increased risk of CRC in women.

The effect of red and processed meats on CRC patients survival was also investigated. An epidemiological investigation by Mattiuzzi et al. (67) showed that red meat and processed meat were related to 1.77% and 1.18% of global CRC deaths, respectively. Prospective observational studies showed that reducing red and processed meat intake in patients with CRC after diagnosis decreased the risk of cancer recurrence and improved the overall survival of patients with early-stage CRC after standard treatment (68).

Therefore, it is necessary to encourage people at high risk of CRC and patients with CRC to reduce their intake of red and processed meats. However, different dietary habits entail different levels of raw meat and meat product consumption and various cooking methods. Therefore, future epidemiological studies should consider the dietary culture of each population to reliably elucidate the effects of processed meat intake, particularly on cancer incidence.

Sugars

A high-sugar diet is associated with obesity and diabetes. Previous studies showed an association between CRC risk and a high prevalence of insulin resistance, obesity, and diabetes (69), but the relationship between a high-sugar diet and CRC risk is not clear.

Animal studies showed that a high-sugar diet promoted the development of CRC (70-72), but the results from clinical trials are more complex. For example, women who consumed more sugary drinks had a slightly higher risk of early-onset CRC than women who consumed less than five ounces (142 g) of sugary drinks per week, and women aged 13 to 18 years who drank eight ounces (227 g) of sugary drinks daily had a 32% increased risk of CRC by age 50, according to the results of a clinical observational study (73). Wang et al. (74) showed that sugar intake in men, in combination with smoking and alcohol consumption, correlated with CRC risk. However, other clinical observational studies reached the opposite conclusion. For example, a cohort study of 243 CRC patients showed that a relatively high intake of sugary beverages had no effect on the development of CRC (75).

Although the results of clinical trials are not as consistent as the results of animal experiments, people are keenly aware of the negative effects of sugar on the human body or the negative effects of sugar on the human body have become ingrained. More clinical trials are needed to confirm the effect of sugar on the occurrence and development of CRC.

Dairy products

Studies have shown that dairy products have protective effects against CRC, which may be related to their high levels of calcium, vitamin D, butyric acid, conjugated linoleic acid (CLA) and lactoferrin (76-78).

Available evidence suggests that the consumption of dairy products may prevent the occurrence of CRC. For example, a prospective cohort study followed 7,216 volunteers who did not initially have CRC for an average of 6 years, during which these participants were questioned about the frequency of various food intake; the results showed that high consumption of dairy products was significantly associated with a reduced CRC risk (79). In a meta-analysis of 15 cohort studies and 14 case-control studies, Barrubés et al. (76) found a consistent, significant decrease in CRC risk associated with higher total consumption of dairy products compared with lower consumption. Subsequently, a prospective cohort study by El Kinany et al. (80) showed a negative association between dairy intake and CRC incidence.

Consumption of dairy products may also affect the survival of CRC patients. A meta-analysis by Jin et al. (81) showed that subjects with a high dairy product intake had a 29% lower risk of dying from CRC than those with a low such intake. A prospective cohort study by Yang et al. (82) evaluated the relationship between dairy products intake and mortality before and after diagnosis in 2,284 patients with CRC and found a negative correlation between dairy product intake and all-cause mortality.

Micronutrients

Calcium, iron, selenium, and other micronutrients are essential for energy production and cell metabolism, and researchers found that they are closely related to the occurrence and development of CRC. CRC patients and people at high risk of CRC should ensure they maintain appropriate micronutrient levels.

Calcium and vitamin D

Dietary calcium supplementation has a certain preventive effect on the occurrence of CRC. Zhang et al. (83) collected dietary intake data from 2,380 CRC patients and 2,389 sex- and age-matched controls. The mean dietary calcium intakes was 406.94 and 468.21 mg/day, respectively, and the intake of dietary calcium reduced the risk of CRC. A prospective cohort study by Lee et al. (84) explored the relationship between dietary calcium intake and CRC development in 119,501 participants aged 40–69 years who were recruited between 2004 and 2013. The results showed that Korean women who adhered to the recommended intake of calcium (700–800 mg/day) had a reduced risk of CRC. A case-control study by Galas et al. (85) showed that a 100 mg/day increase in dietary calcium intake was associated with a 5% decrease in CRC risk, and participants taking >1,000 mg/day calcium had a 37% lower risk of CRC.

Some studies have revealed a relationship between calcium levels and quality of life in CRC patients. A prospective study by Yang et al. (86) evaluated the association of calcium intake with CRC-specific and overall mortality after diagnosis in 1,660 patients with nonmetastatic CRC. The results showed that participants who increased calcium intake by at least 300 mg/day had an HR of 0.64 for CRC-specific mortality compared to those who did not appreciably alter their supplemental calcium intake (change <150 mg/day). However, participants who decreased their intake at least 300 mg/day had an HR of 1.23. The prospective cohort study by Um et al. (87) revealed that Ca²⁺ may be associated with a reduced risk of CRC mortality.

Vitamin D deficiency affects calcium absorption (88). The recommended dietary allowance (RDA) for vitamin D of 15 µg/day for adults between 51 and 70 years and 20 µg/day for older adults (>70 years) is widely established (89). Studies have shown an association between vitamin D deficiency and the occurrence of almost all cancers, with CRC being the most relevant type (90).

A recent case-control study found that higher dietary intake of vitamin D and calcium was associated with 47% and 50% reductions, respectively, in CRC risk (91). Consistent with this result, a meta-analysis of nine case-control studies found that the risk of CRC decreased with increased dietary vitamin D intake (92); this same conclusion was reached in another meta-analysis of 17 cohort studies (93).

Animal studies (94) have shown that vitamin D supplementation has potential as an adjuvant therapy for CRC. A randomized controlled trial by Haidari et al. (60) revealed that vitamin D may be a novel adjuvant treatment because it can reduce inflammatory biomarkers and treatment resistance in CRC patients.

Selenium

Patients with CRC have low levels of selenium. Haidari et al. (60) measured the selenium concentration in the blood of 40 patients before surgery, and further analysis showed that selenium levels in the blood and colorectal tissue were significantly lower in patients with metastatic disease. Some observational studies have reported the anticancer effects of selenium. A case-control study by Luo et al. (95) examined the independent and combined effects of dietary zinc and selenium intake in 493 patients with CRC and 498 controls. Notably, there was a negative correlation between selenium intake and CRC risk. Tsilidis et al. (96) investigated the association of genetically predicted selenium concentration with CRC risk using Mendelian randomization (MR). The results showed that selenium intake negatively correlated with the incidence of CRC. In a double-blind, placebo-controlled, randomized trial, 200 µg/day selenium was prescribed to 1,312 subjects with a history of nonmelanoma skin cancer in the southeastern United States, and these participants were followed for 4.5 years to study the protective effects of selenium against cancer. The results showed no effect of selenium on the primary outcome, but there was a significant 58% reduction in CRC-related mortality (97).

B Vitamins

B vitamins, including folic acid (vitamin B9), riboflavin (vitamin B2), pyridoxine (vitamin B6), and cobalamin (vitamin B12), are essential for DNA methylation, synthesis, stability, and repair (98).

Evidence from epidemiological, zoological, and clinical studies suggests that vitamin B intake influences the development of CRC. A meta-analysis of a prospective study revealed a significant linear decrease in CRC risk with higher intake of vitamin B6; for each additional 1, 3, and 5 mg increase in vitamin B6 intake, the risk of CRC decreased 4%, 11% and 17%, respectively (99). Another meta-analysis (100) of 14 studies that reported vitamin B2 intake and 2 studies that reported blood vitamin B2 concentrations examined the relationship between vitamin B2 and CRC risk. The dose-response model showed a nonlinear trend, with a 10% reduction in CRC risk when vitamin B2 intake increased to 5 mg/day.

Vitamin B is associated with CRC risk and quality of life in CRC patients. Koole et al. (101) reported that folic acid supplementation before and after diagnosis improved the quality of life of CRC patients.

Discussion

This evaluation relevant literature from the last two decades on the association of diet patterns and factors with CRC demonstrates a role for diet in the prevention and treatment of CRC. No specific nutritional regimen has been shown to be effective in CRC patients. Thus, we encourage individuals at high risk of CRC to increase their DF, dairy products, and omega-3 fatty acids and to avoid excessive intake of sugar, red meat, and processed meat. For CRC patients, the MD, vegetarian diet, and KD may be implemented as a component of combination therapy. It should be noted that these diets should be followed under the care of a dietitian, and the supplementation of trace elements and vitamins should be emphasized to avoid the risk of micronutrient deficiencies or, worse, malnutrition.

Summary and outlook

Diet is an integral part of the daily lives of patients and may be used effectively to provide daily nutrition and prevent and treat disease. People at high risk of CRC should focus on maintaining a healthy lifestyle to reduce or delay the incidence of cancer. CRC patients can improve their quality of life by improving dietary habits, following specific dietary patterns, or taking dietary supplements to alleviate disease.

Dietary intervention is part of the clinical prevention and treatment strategy for CRC, and it has achieved significant results. It may be used independently or in combination with immunosuppressants and other drugs to achieve better therapeutic results. The mechanism by which dietary intervention affects the development of CRC are not clear. Studies involving the microbiome, metabolome and proteome are beginning to provide evidence that will help guide more targeted dietary treatments in the future. The mechanism of dietary therapy must be further studied in clinical and preclinical models. Diet therapy is not effective in all patients, and more effective and personalized diets represent the new direction of diet therapy.

Acknowledgments

We would like to thank AJE Editing Service (https://secure.aje.com/en/certificate) for English language editing.

Funding: This work was supported by grants from the National Natural Science Foundation of China (No. 82173240 and No. 81900483).

Footnote

Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-32/rc

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-32/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer 2021; Epub ahead of print. [Crossref] [PubMed]
2. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023-75. [Crossref] [PubMed]
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34. [Crossref] [PubMed]
4. Schulpen M, van den Brandt PA. Adherence to the Mediterranean Diet and Overall Cancer Incidence: The Netherlands Cohort Study. J Acad Nutr Diet 2021;121:242-52. [Crossref] [PubMed]
5. Fitó M, Cladellas M, de la Torre R, et al. Anti-inflammatory effect of virgin olive oil in stable coronary disease patients: a randomized, crossover, controlled trial. Eur J Clin Nutr 2008;62:570-4. [Crossref] [PubMed]
6. Zhong Y, Zhu Y, Li Q, et al. Association between Mediterranean diet adherence and colorectal cancer: a dose-response meta-analysis. Am J Clin Nutr 2020;111:1214-25. [Crossref] [PubMed]
7. Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: a systematic review and meta-analysis of observational studies. Int J Cancer 2014;135:1884-97. [Crossref] [PubMed]
8. Rosato V, Guercio V, Bosetti C, et al. Mediterranean diet and colorectal cancer risk: a pooled analysis of three Italian case-control studies. Br J Cancer 2016;115:862-5. [Crossref] [PubMed]
9. Van Blarigan EL, Zhang S, Ou FS, et al. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Netw Open 2020;3:e2023500. [Crossref] [PubMed]
10. Jacobs S, Harmon BE, Ollberding NJ, et al. Among 4 Diet Quality Indexes, Only the Alternate Mediterranean Diet Score Is Associated with Better Colorectal Cancer Survival and Only in African American Women in the Multiethnic Cohort. J Nutr 2016;146:1746-55. [Crossref] [PubMed]
11. Bloomfield HE, Koeller E, Greer N, et al. Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake: A Systematic Review and Meta-analysis. Ann Intern Med 2016;165:491-500. [Crossref] [PubMed]
12. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117-24. [Crossref] [PubMed]
13. Fung TT, Kashambwa R, Sato K, et al. Post diagnosis diet quality and colorectal cancer survival in women. PLoS One 2014;9:e115377. [Crossref] [PubMed]
14. Tangestani H, Salari-Moghaddam A, Ghalandari H, et al. Adherence to the Dietary Approaches to Stop Hypertension (DASH) dietary pattern reduces the risk of colorectal cancer: A systematic review and meta-analysis. Clin Nutr 2020;39:2975-81. [Crossref] [PubMed]
15. Vargas AJ, Neuhouser ML, George SM, et al. Diet Quality and Colorectal Cancer Risk in the Women's Health Initiative Observational Study. Am J Epidemiol 2016;184:23-32. [Crossref] [PubMed]
16. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab 2014;19:181-92. [Crossref] [PubMed]
17. Brandhorst S, Choi IY, Wei M, et al. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab 2015;22:86-99. [Crossref] [PubMed]
18. What is a vegetarian? Vegetarian Journal’s Foodservice. 2003. Available online: https://www.vegsoc.org/
19. Orlich MJ, Singh PN, Sabaté J, et al. Vegetarian dietary patterns and the risk of colorectal cancers. JAMA Intern Med 2015;175:767-76. [Crossref] [PubMed]
20. Gilsing AM, Schouten LJ, Goldbohm RA, et al. Vegetarianism, low meat consumption and the risk of colorectal cancer in a population based cohort study. Sci Rep 2015;5:13484. [Crossref] [PubMed]
21. Sanjoaquin MA, Appleby PN, Thorogood M, et al. Nutrition, lifestyle and colorectal cancer incidence: a prospective investigation of 10998 vegetarians and non-vegetarians in the United Kingdom. Br J Cancer 2004;90:118-21. [Crossref] [PubMed]
22. Weber DD, Aminzadeh-Gohari S, Tulipan J, et al. Ketogenic diet in the treatment of cancer - Where do we stand? Mol Metab 2020;33:102-21. [Crossref] [PubMed]
23. Zhang N, Liu C, Jin L, et al. Ketogenic Diet Elicits Antitumor Properties through Inducing Oxidative Stress, Inhibiting MMP-9 Expression, and Rebalancing M1/M2 Tumor-Associated Macrophage Phenotype in a Mouse Model of Colon Cancer. J Agric Food Chem 2020;68:11182-96. [Crossref] [PubMed]
24. Nakamura K, Tonouchi H, Sasayama A, et al. A Ketogenic Formula Prevents Tumor Progression and Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice. Nutrients 2018;10:206. [Crossref] [PubMed]
25. Klement RJ, Koebrunner PS, Meyer D, et al. Impact of a ketogenic diet intervention during radiotherapy on body composition: IV. Final results of the KETOCOMP study for rectal cancer patients. Clin Nutr 2021;40:4674-84. [Crossref] [PubMed]
26. Tulipan J, Kofler B. Implementation of a Low-Carbohydrate Diet Improves the Quality of Life of Cancer Patients - An Online Survey. Front Nutr 2021;8:661253. [Crossref] [PubMed]
27. Klement RJ, Schäfer G, Sweeney RA. A ketogenic diet exerts beneficial effects on body composition of cancer patients during radiotherapy: An interim analysis of the KETOCOMP study. J Tradit Complement Med 2020;10:180-7. [Crossref] [PubMed]
28. Caan BJ, Cespedes Feliciano EM, Kroenke CH. The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint. Cancer Res 2018;78:1906-12. [Crossref] [PubMed]
29. Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: II. Protocol of a randomised phase I study (KETOCOMP). Clin Nutr ESPEN 2016;12:e1-6. [Crossref] [PubMed]
30. Sofi F, Macchi C, Abbate R, et al. Mediterranean diet and health. Biofactors 2013;39:335-42. [Crossref] [PubMed]
31. Bracale R, Vaccaro CM, Coletta V, et al. Nutrition behaviour and compliance with the Mediterranean diet pyramid recommendations: an Italian survey-based study. Eat Weight Disord 2020;25:1789-98. [Crossref] [PubMed]
32. Fung TT, McCullough ML, Newby PK, et al. Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2005;82:163-73. [Crossref] [PubMed]
33. Heidari Z, Mohammadi E, Aghamohammadi V, et al. Dietary Approaches to Stop Hypertension (DASH) diets and breast cancer among women: a case control study. BMC Cancer 2020;20:708. [Crossref] [PubMed]
34. Rangan P, Choi I, Wei M, et al. Fasting-Mimicking Diet Modulates Microbiota and Promotes Intestinal Regeneration to Reduce Inflammatory Bowel Disease Pathology. Cell Rep 2019;26:2704-19.e6. [Crossref] [PubMed]
35. Caffa I, Spagnolo V, Vernieri C, et al. Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature 2020;583:620-4. [Crossref] [PubMed]
36. Nencioni A, Caffa I, Cortellino S, et al. Fasting and cancer: molecular mechanisms and clinical application. Nat Rev Cancer 2018;18:707-19. [Crossref] [PubMed]
37. Castejón M, Plaza A, Martinez-Romero J, et al. Energy Restriction and Colorectal Cancer: A Call for Additional Research. Nutrients 2020;12:114. [Crossref] [PubMed]
38. E S. Intake of mulberry 1-deoxynojirimycin prevents colorectal cancer in mice. J Clin Biochem Nutr 2017;61:47-52. [Crossref] [PubMed]
39. Weng ML, Chen WK, Chen XY, et al. Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression. Nat Commun 2020;11:1869. [Crossref] [PubMed]
40. Beig BB. A prática vegetariana em Rio Claro: corpo, espírito e natureza. 2008.
41. Godos J, Bella F, Sciacca S, et al. Vegetarianism and breast, colorectal and prostate cancer risk: an overview and meta-analysis of cohort studies. J Hum Nutr Diet 2017;30:349-59. [Crossref] [PubMed]
42. Erben V, Carr PR, Holleczek B, et al. Dietary patterns and risk of advanced colorectal neoplasms: A large population based screening study in Germany. Prev Med 2018;111:101-9. [Crossref] [PubMed]
43. Dinu M, Abbate R, Gensini GF, et al. Vegetarian, vegan diets and multiple health outcomes: A systematic review with meta-analysis of observational studies. Crit Rev Food Sci Nutr 2017;57:3640-9. [Crossref] [PubMed]
44. Ginter E. Vegetarian diets, chronic diseases and longevity. Bratisl Lek Listy 2008;109:463-6. [PubMed]
45. Davis JJ, Fournakis N, Ellison J. Ketogenic Diet for the Treatment and Prevention of Dementia: A Review. J Geriatr Psychiatry Neurol 2021;34:3-10. [Crossref] [PubMed]
46. Yu EYW, Wesselius A, Mehrkanoon S, et al. Grain and dietary fiber intake and bladder cancer risk: a pooled analysis of prospective cohort studies. Am J Clin Nutr 2020;112:1252-66. [Crossref] [PubMed]
47. Peto R. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer 2011;105:S1. [Crossref] [PubMed]
48. Tedstone A, Lund V, Sanderson P, et al. Carbohydrates and Health. SACN 2015.
49. O'Keefe SJ. Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol 2016;13:691-706. [Crossref] [PubMed]
50. Song M, Wu K, Meyerhardt JA, et al. Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol 2018;4:71-9. [Crossref] [PubMed]
51. Mayor S. Eating more fibre linked to reduced risk of non-communicable diseases and death, review finds. BMJ 2019;364:l159. [Crossref]
52. Beyaz S, Mana MD, Roper J, et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature 2016;531:53-8. [Crossref] [PubMed]
53. Schulz MD, Atay C, Heringer J, et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature 2014;514:508-12. [Crossref] [PubMed]
54. Ocvirk S, O'Keefe SJ. Influence of Bile Acids on Colorectal Cancer Risk: Potential Mechanisms Mediated by Diet - Gut Microbiota Interactions. Curr Nutr Rep 2017;6:315-22. [Crossref] [PubMed]
55. Wan Y, Wang F, Yuan J, et al. Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial. Gut 2019;68:1417-29. [Crossref] [PubMed]
56. Zhong X, Fang YJ, Pan ZZ, et al. Dietary fat, fatty acid intakes and colorectal cancer risk in Chinese adults: a case-control study. Eur J Cancer Prev 2013;22:438-47. [Crossref] [PubMed]
57. Kim M, Park K. Dietary Fat Intake and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis of Prospective Studies. Nutrients 2018;10:1963. [Crossref] [PubMed]
58. Nakamura T, Ishikawa H, Takeyama I, et al. Excessive fat restriction might promote the recurrence of colorectal tumors. Nutr Cancer 2010;62:154-63. [Crossref] [PubMed]
59. Djuricic I, Calder PC. Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021. Nutrients 2021;13:2421. [Crossref] [PubMed]
60. Haidari F, Abiri B, Iravani M, et al. Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer: a study protocol for a double blind randomized controlled trial. Trials 2019;20:682. [Crossref] [PubMed]
61. Golkhalkhali B, Rajandram R, Paliany AS, et al. Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial. Asia Pac J Clin Oncol 2018;14:179-91. [Crossref] [PubMed]
62. Sorensen LS, Thorlacius-Ussing O, Rasmussen HH, et al. Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B4 and leukotriene B5 production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. Nutrients 2014;6:4043-57. [Crossref] [PubMed]
63. Kim Y, Kim J. Intake or Blood Levels of n-3 Polyunsaturated Fatty Acids and Risk of Colorectal Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Cancer Epidemiol Biomarkers Prev 2020;29:288-99. [Crossref] [PubMed]
64. Tan J, Chen YX. Dietary and Lifestyle Factors Associated with Colorectal Cancer Risk and Interactions with Microbiota: Fiber, Red or Processed Meat and Alcoholic Drinks. Gastrointest Tumors 2016;3:17-24. [Crossref] [PubMed]
65. Bradbury KE, Murphy N, Key TJ. Diet and colorectal cancer in UK Biobank: a prospective study. Int J Epidemiol 2020;49:246-58. [Crossref] [PubMed]
66. Mehta SS, Arroyave WD, Lunn RM, et al. A Prospective Analysis of Red and Processed Meat Consumption and Risk of Colorectal Cancer in Women. Cancer Epidemiol Biomarkers Prev 2020;29:141-50. [Crossref] [PubMed]
67. Mattiuzzi C, Lippi G. Epidemiologic Burden of Red and Processed Meat Intake on Colorectal Cancer Mortality. Nutr Cancer 2021;73:562-7. [Crossref] [PubMed]
68. Meyerhardt JA. Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions. Semin Oncol 2011;38:533-41. [Crossref] [PubMed]
69. Reis DJ, Ilardi SS, Namekata MS, et al. The depressogenic potential of added dietary sugars. Med Hypotheses 2020;134:109421. [Crossref] [PubMed]
70. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91-106. [Crossref] [PubMed]
71. Xiang W, Shi R, Zhang D, et al. Dietary fats suppress the peritoneal seeding of colorectal cancer cells through the TLR4/Cxcl10 axis in adipose tissue macrophages. Signal Transduct Target Ther 2020;5:239. [Crossref] [PubMed]
72. Yang IP, Tsai HL, Huang CW, et al. High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2. Oncotarget 2016;7:18837-50. [Crossref] [PubMed]
73. Hur J, Otegbeye E, Joh HK, et al. Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women. Gut 2021;70:2330-6. [Crossref] [PubMed]
74. Wang Z, Uchida K, Ohnaka K, et al. Sugars, sucrose and colorectal cancer risk: the Fukuoka colorectal cancer study. Scand J Gastroenterol 2014;49:581-8. [Crossref] [PubMed]
75. Arthur RS, Kirsh VA, Mossavar-Rahmani Y, et al. Sugar-containing beverages and their association with risk of breast, endometrial, ovarian and colorectal cancers among Canadian women. Cancer Epidemiol 2021;70:101855. [Crossref] [PubMed]
76. Barrubés L, Babio N, Becerra-Tomás N, et al. Association Between Dairy Product Consumption and Colorectal Cancer Risk in Adults: A Systematic Review and Meta-Analysis of Epidemiologic Studies. Adv Nutr 2019;10:S190-211. [Crossref] [PubMed]
77. Norat T, Riboli E. Dairy products and colorectal cancer. A review of possible mechanisms and epidemiological evidence. Eur J Clin Nutr 2003;57:1-17. [Crossref] [PubMed]
78. Touvier M, Chan DS, Lau R, et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011;20:1003-16. [Crossref] [PubMed]
79. Barrubés L, Babio N, Mena-Sánchez G, et al. Dairy product consumption and risk of colorectal cancer in an older mediterranean population at high cardiovascular risk. Int J Cancer 2018;143:1356-66. [Crossref] [PubMed]
80. El Kinany K, Mint Sidi Deoula M, Hatime Z, et al. Consumption of modern and traditional Moroccan dairy products and colorectal cancer risk: a large case control study. Eur J Nutr 2020;59:953-63. [Crossref] [PubMed]
81. Jin S, Kim Y, Je Y. Dairy Consumption and Risks of Colorectal Cancer Incidence and Mortality: A Meta-analysis of Prospective Cohort Studies. Cancer Epidemiol Biomarkers Prev 2020;29:2309-22. [Crossref] [PubMed]
82. Yang B, McCullough ML, Gapstur SM, et al. Calcium, vitamin D, dairy products, and mortality among colorectal cancer survivors: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2014;32:2335-43. [Crossref] [PubMed]
83. Zhang X, Fang YJ, Feng XL, et al. Higher intakes of dietary vitamin D, calcium and dairy products are inversely associated with the risk of colorectal cancer: a case-control study in China. Br J Nutr 2020;123:699-711. [Crossref] [PubMed]
84. Lee J, Shin A, Choi JY, et al. Adherence to the Recommended Intake of Calcium and Colorectal Cancer Risk in the HEXA Study. Cancer Res Treat 2021;53:140-7. [Crossref] [PubMed]
85. Galas A, Augustyniak M, Sochacka-Tatara E. Does dietary calcium interact with dietary fiber against colorectal cancer? A case-control study in Central Europe. Nutr J 2013;12:134. [Crossref] [PubMed]
86. Yang W, Ma Y, Smith-Warner S, et al. Calcium Intake and Survival after Colorectal Cancer Diagnosis. Clin Cancer Res 2019;25:1980-8. [Crossref] [PubMed]
87. Um CY, Prizment A, Hong CP, et al. Associations of calcium and dairy product intakes with all-cause, all-cancer, colorectal cancer and CHD mortality among older women in the Iowa Women's Health Study. Br J Nutr 2019;121:1188-200. [Crossref] [PubMed]
88. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 2006;35:217-20. [Crossref] [PubMed]
89. Hernández-Alonso P, Canudas S, Boughanem H, et al. Dietary vitamin D intake and colorectal cancer risk: a longitudinal approach within the PREDIMED study. Eur J Nutr 2021;60:4367-78. [Crossref] [PubMed]
90. Crosara Teixeira M, Braghiroli MI, Sabbaga J, et al. Primary prevention of colorectal cancer: myth or reality? World J Gastroenterol 2014;20:15060-9. [Crossref] [PubMed]
91. Zhang X, Fang YJ, Feng XL, et al. Interactions Between Vitamin D and Calcium Intake, Vitamin D Receptor Genetic Polymorphisms, and Colorectal Cancer Risk. Dig Dis Sci 2021;66:1895-905. [Crossref] [PubMed]
92. Ma Y, Zhang P, Wang F, et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011;29:3775-82. [Crossref] [PubMed]
93. Huncharek M, Muscat J, Kupelnick B. Colorectal cancer risk and dietary intake of calcium, vitamin D, and dairy products: a meta-analysis of 26,335 cases from 60 observational studies. Nutr Cancer 2009;61:47-69. [Crossref] [PubMed]
94. Zhou X, Chen C, Zhong YN, et al. Effect and mechanism of vitamin D on the development of colorectal cancer based on intestinal flora disorder. J Gastroenterol Hepatol 2020;35:1023-31. [Crossref] [PubMed]
95. Luo H, Fang YJ, Zhang X, et al. Association between Dietary Zinc and Selenium Intake, Oxidative Stress-Related Gene Polymorphism, and Colorectal Cancer Risk in Chinese Population - A Case-Control Study. Nutr Cancer 2021;73:1621-30. [Crossref] [PubMed]
96. Tsilidis KK, Papadimitriou N, Dimou N, et al. Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. Am J Clin Nutr 2021;113:1490-502. [PubMed]
97. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11:630-9. [PubMed]
98. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology 2015;148:1244-60.e16. [Crossref] [PubMed]
99. Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA 2010;303:1077-83. [Crossref] [PubMed]
100. Ben S, Du M, Ma G, et al. Vitamin B2 intake reduces the risk for colorectal cancer: a dose-response analysis. Eur J Nutr 2019;58:1591-602. [Crossref] [PubMed]
101. Koole JL, Bours MJL, Geijsen AJMR, et al. Circulating B-vitamin biomarkers and B-vitamin supplement use in relation to quality of life in patients with colorectal cancer: results from the FOCUS consortium. Am J Clin Nutr 2021;113:1468-81. [Crossref] [PubMed]